GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Balance Sheet History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| EQUITY AND LIABILITIES | |||||
| Share Capital | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr |
| Equity - Authorised | ₹237 Cr | ₹237 Cr | ₹237 Cr | ₹237 Cr | ₹237 Cr |
| Equity - Issued | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr |
| Equity Paid Up | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr |
| Equity Shares Forfeited | - | - | - | - | - |
| Adjustments to Equity | - | - | - | - | - |
| Preference Capital Paid Up | - | - | - | - | - |
| Face Value | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 |
| Share Warrants & Outstandings | ₹9.06 Cr | ₹18 Cr | ₹18 Cr | ₹16 Cr | ₹22 Cr |
| Total Reserves | ₹8,812 Cr | ₹7,801 Cr | ₹9,428 Cr | ₹9,042 Cr | ₹7,015 Cr |
| Securities Premium | ₹1,687 Cr | ₹1,687 Cr | ₹1,685 Cr | ₹1,685 Cr | ₹1,685 Cr |
| Capital Reserves | ₹0.10 Cr | ₹0.10 Cr | ₹0.10 Cr | ₹0.10 Cr | ₹0.10 Cr |
| Profit & Loss Account Balance | ₹8,799 Cr | ₹7,870 Cr | ₹9,457 Cr | ₹9,211 Cr | ₹7,234 Cr |
| General Reserves | ₹115 Cr | ₹146 Cr | ₹146 Cr | ₹146 Cr | ₹146 Cr |
| Other Reserves | ₹-1,788 Cr | ₹-1,901 Cr | ₹-1,860 Cr | ₹-2,000 Cr | ₹-2,050 Cr |
| Reserve excluding Revaluation Reserve | ₹8,812 Cr | ₹7,801 Cr | ₹9,428 Cr | ₹9,042 Cr | ₹7,015 Cr |
| Revaluation reserve | - | - | - | - | - |
| Shareholder's Funds | ₹8,849 Cr | ₹7,848 Cr | ₹9,474 Cr | ₹9,087 Cr | ₹7,065 Cr |
| Minority Interest | ₹-0.37 Cr | ₹-0.38 Cr | ₹365 Cr | ₹351 Cr | ₹-0.35 Cr |
| Long-Term Borrowings | - | - | - | - | - |
| Secured Loans | - | - | - | - | - |
| Non Convertible Debentures | - | - | - | - | - |
| Converible Debentures & Bonds | - | - | - | - | - |
| Packing Credit - Bank | - | - | - | - | - |
| Inter Corporate & Security Deposit | - | - | - | - | - |
| Term Loans - Banks | - | - | - | - | - |
| Term Loans - Institutions | - | - | - | - | - |
| Other Secured | - | - | - | - | - |
| Unsecured Loans | ₹513 Cr | - | ₹3,852 Cr | ₹2,572 Cr | ₹3,889 Cr |
| Fixed Deposits - Public | - | - | - | - | - |
| Loans and advances from subsidiaries | - | - | - | - | - |
| Inter Corporate Deposits (Unsecured) | - | - | - | - | - |
| Foreign Currency Convertible Notes | - | - | - | ₹729 Cr | ₹1,017 Cr |
| Long Term Loan in Foreign Currency | - | ₹157 Cr | ₹2,806 Cr | ₹2,572 Cr | ₹2,095 Cr |
| Loans - Banks | ₹513 Cr | - | ₹1,191 Cr | - | ₹1,062 Cr |
| Loans - Govt. | - | - | - | - | - |
| Loans - Others | - | - | - | - | - |
| Other Unsecured Loan | - | ₹-157 Cr | ₹-146 Cr | ₹-729 Cr | ₹-286 Cr |
| Deferred Tax Assets / Liabilities | ₹-1,066 Cr | ₹-1,049 Cr | ₹-1,805 Cr | ₹-1,655 Cr | ₹-1,506 Cr |
| Deferred Tax Assets | ₹1,323 Cr | ₹1,432 Cr | ₹2,046 Cr | ₹1,938 Cr | ₹1,823 Cr |
| Deferred Tax Liability | ₹257 Cr | ₹383 Cr | ₹240 Cr | ₹283 Cr | ₹318 Cr |
| Other Long Term Liabilities | ₹662 Cr | ₹692 Cr | ₹575 Cr | ₹352 Cr | ₹421 Cr |
| Long Term Trade Payables | - | - | - | - | - |
| Long Term Provisions | - | - | - | - | - |
| Total Non-Current Liabilities | ₹109 Cr | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr | ₹2,804 Cr |
| Current Liabilities | - | - | - | - | - |
| Trade Payables | ₹2,580 Cr | ₹2,536 Cr | ₹2,000 Cr | ₹2,289 Cr | ₹2,238 Cr |
| Sundry Creditors | ₹2,580 Cr | ₹2,536 Cr | ₹2,000 Cr | ₹2,289 Cr | ₹2,238 Cr |
| Acceptances | - | - | - | - | - |
| Due to Subsidiaries- Trade Payables | - | - | - | - | - |
| Other Current Liabilities | ₹1,082 Cr | ₹1,517 Cr | ₹1,605 Cr | ₹1,446 Cr | ₹886 Cr |
| Bank Overdraft / Short term credit | - | - | - | - | - |
| Advances received from customers | - | - | - | - | - |
| Interest Accrued But Not Due | ₹3.34 Cr | ₹4.40 Cr | ₹43 Cr | ₹14 Cr | ₹18 Cr |
| Share Application Money | - | - | - | - | - |
| Current maturity of Debentures & Bonds | - | - | - | - | - |
| Current maturity - Others | - | - | - | - | - |
| Other Liabilities | ₹1,078 Cr | ₹1,513 Cr | ₹1,562 Cr | ₹1,433 Cr | ₹868 Cr |
| Short Term Borrowings | ₹1,681 Cr | ₹833 Cr | ₹350 Cr | ₹370 Cr | ₹513 Cr |
| Secured ST Loans repayable on Demands | ₹299 Cr | - | - | - | - |
| Working Capital Loans- Sec | ₹299 Cr | - | - | - | - |
| Buyers Credits - Unsec | - | - | - | - | - |
| Commercial Borrowings- Unsec | - | - | - | - | - |
| Other Unsecured Loans | ₹1,084 Cr | ₹833 Cr | ₹350 Cr | ₹370 Cr | ₹513 Cr |
| Short Term Provisions | ₹624 Cr | ₹932 Cr | ₹591 Cr | ₹585 Cr | ₹564 Cr |
| Proposed Equity Dividend | - | - | - | - | - |
| Provision for Corporate Dividend Tax | - | - | - | - | - |
| Provision for Tax | ₹28 Cr | ₹291 Cr | ₹98 Cr | ₹93 Cr | ₹50 Cr |
| Provision for post retirement benefits | ₹112 Cr | ₹101 Cr | ₹88 Cr | ₹98 Cr | ₹115 Cr |
| Preference Dividend | - | - | - | - | - |
| Other Provisions | ₹484 Cr | ₹540 Cr | ₹404 Cr | ₹394 Cr | ₹399 Cr |
| Total Current Liabilities | ₹5,967 Cr | ₹5,819 Cr | ₹4,546 Cr | ₹4,689 Cr | ₹4,201 Cr |
| Total Liabilities | ₹14,925 Cr | ₹13,309 Cr | ₹17,566 Cr | ₹15,397 Cr | ₹14,069 Cr |
| ASSETS | |||||
| Gross Block | ₹10,365 Cr | ₹9,620 Cr | ₹10,360 Cr | ₹10,213 Cr | ₹8,732 Cr |
| Less: Accumulated Depreciation | ₹5,878 Cr | ₹5,409 Cr | ₹4,938 Cr | ₹4,326 Cr | ₹3,603 Cr |
| Less: Impairment of Assets | - | - | - | - | - |
| Net Block | ₹4,487 Cr | ₹4,210 Cr | ₹5,422 Cr | ₹5,887 Cr | ₹5,129 Cr |
| Lease Adjustment A/c | - | - | - | - | - |
| Capital Work in Progress | ₹542 Cr | ₹419 Cr | ₹1,066 Cr | ₹921 Cr | ₹1,218 Cr |
| Non Current Investments | ₹56 Cr | ₹790 Cr | ₹45 Cr | ₹50 Cr | ₹25 Cr |
| Long Term Investment | ₹56 Cr | ₹790 Cr | ₹45 Cr | ₹50 Cr | ₹25 Cr |
| Quoted | ₹0.11 Cr | ₹745 Cr | ₹0.07 Cr | ₹0.05 Cr | ₹0.07 Cr |
| Unquoted | ₹56 Cr | ₹45 Cr | ₹45 Cr | ₹50 Cr | ₹25 Cr |
| Long Term Loans & Advances | ₹243 Cr | ₹212 Cr | ₹181 Cr | ₹161 Cr | ₹146 Cr |
| Other Non Current Assets | ₹9.23 Cr | ₹7.42 Cr | ₹3.46 Cr | ₹6.70 Cr | ₹28 Cr |
| Total Non-Current Assets | ₹5,630 Cr | ₹5,881 Cr | ₹6,840 Cr | ₹7,115 Cr | ₹6,709 Cr |
| Current Assets Loans & Advances | - | - | - | - | - |
| Currents Investments | - | - | - | - | - |
| Quoted | - | - | - | - | - |
| Unquoted | - | - | - | - | - |
| Inventories | ₹3,029 Cr | ₹2,513 Cr | ₹2,374 Cr | ₹2,500 Cr | ₹2,277 Cr |
| Raw Materials | ₹832 Cr | ₹580 Cr | ₹649 Cr | ₹703 Cr | ₹528 Cr |
| Work-in Progress | ₹115 Cr | ₹103 Cr | ₹84 Cr | ₹402 Cr | ₹439 Cr |
| Finished Goods | ₹1,397 Cr | ₹1,193 Cr | ₹1,020 Cr | ₹846 Cr | ₹839 Cr |
| Packing Materials | ₹384 Cr | ₹314 Cr | ₹298 Cr | ₹269 Cr | ₹230 Cr |
| Stores  and Spare | ₹89 Cr | ₹111 Cr | ₹114 Cr | ₹104 Cr | ₹107 Cr |
| Other Inventory | ₹211 Cr | ₹213 Cr | ₹209 Cr | ₹174 Cr | ₹133 Cr |
| Sundry Debtors | ₹3,342 Cr | ₹1,858 Cr | ₹3,665 Cr | ₹3,101 Cr | ₹2,572 Cr |
| Debtors more than Six months | ₹468 Cr | ₹396 Cr | ₹363 Cr | ₹302 Cr | ₹396 Cr |
| Debtors Others | ₹3,007 Cr | ₹1,593 Cr | ₹3,443 Cr | ₹2,929 Cr | ₹2,283 Cr |
| Cash and Bank | ₹1,705 Cr | ₹1,659 Cr | ₹1,160 Cr | ₹1,412 Cr | ₹1,139 Cr |
| Cash in hand | ₹1.07 Cr | ₹0.98 Cr | ₹1.04 Cr | ₹1.69 Cr | ₹1.61 Cr |
| Balances at Bank | ₹1,704 Cr | ₹1,658 Cr | ₹1,159 Cr | ₹1,410 Cr | ₹1,138 Cr |
| Other cash and bank balances | - | - | - | - | - |
| Other Current Assets | ₹145 Cr | ₹178 Cr | ₹317 Cr | ₹297 Cr | ₹671 Cr |
| Interest accrued on Investments | - | - | - | - | - |
| Interest accrued on Debentures | - | - | - | - | - |
| Deposits with Government | - | - | - | - | - |
| Interest accrued and or due on loans | - | - | - | - | - |
| Prepaid Expenses | ₹105 Cr | ₹27 Cr | ₹227 Cr | ₹220 Cr | ₹220 Cr |
| Other current_assets | ₹40 Cr | ₹152 Cr | ₹89 Cr | ₹78 Cr | ₹451 Cr |
| Short Term Loans and Advances | ₹1,075 Cr | ₹1,219 Cr | ₹908 Cr | ₹972 Cr | ₹700 Cr |
| Advances recoverable in cash or in kind | ₹521 Cr | ₹526 Cr | ₹382 Cr | ₹457 Cr | ₹633 Cr |
| Advance income tax and TDS | - | - | - | - | - |
| Amounts due from directors | - | - | - | - | - |
| Due From Subsidiaries | - | - | - | - | - |
| Inter corporate deposits | - | - | - | - | - |
| Corporate Deposits | - | - | - | - | - |
| Other Loans & Advances | ₹554 Cr | ₹693 Cr | ₹526 Cr | ₹516 Cr | ₹68 Cr |
| Total Current Assets | ₹9,295 Cr | ₹7,428 Cr | ₹8,424 Cr | ₹8,282 Cr | ₹7,360 Cr |
| Net Current Assets (Including Current Investments) | ₹3,328 Cr | ₹1,609 Cr | ₹3,877 Cr | ₹3,593 Cr | ₹3,159 Cr |
| Miscellaneous Expenses not written off | - | - | - | - | - |
| Total Assets | ₹14,925 Cr | ₹13,309 Cr | ₹17,566 Cr | ₹15,397 Cr | ₹14,069 Cr |
| Contingent Liabilities | ₹800 Cr | ₹1,063 Cr | ₹337 Cr | ₹361 Cr | ₹384 Cr |
| Total Debt | ₹2,194 Cr | ₹991 Cr | ₹4,348 Cr | ₹3,670 Cr | ₹4,687 Cr |
| Book Value | - | 277.46 | 335.13 | 321.45 | 249.60 |
| Adjusted Book Value | 313.28 | 277.46 | 335.13 | 321.45 | 249.60 |
Compare Balance Sheet of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹56,179.0 Cr | 0.3% | 5.8% | 29.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,708.0 Cr | -2.9% | -1.8% | -2.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,975.0 Cr | 2.1% | 0.2% | 9.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹128,619.0 Cr | 0.5% | 2.2% | 11.2% | Stock Analytics | |
| CIPLA | ₹122,539.0 Cr | 0.7% | -0.8% | 3.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,741.0 Cr | -0.1% | 2.5% | 2.5% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 0.3% |
5.8% |
29.2% |
| SENSEX | -0.4% |
-0.3% |
3.9% |
You may also like the below Video Courses